<DOC>
	<DOCNO>NCT02454179</DOCNO>
	<brief_summary>Study combination acalabrutinib ( ACP-196 ) pembrolizumab subject advance head neck squamous cell carcinoma .</brief_summary>
	<brief_title>Study Combination Acalabrutinib ( ACP-196 ) Pembrolizumab Advanced Head Neck Squamous Cell Carcinoma</brief_title>
	<detailed_description />
	<mesh_term>Carcinoma</mesh_term>
	<mesh_term>Carcinoma , Squamous Cell</mesh_term>
	<mesh_term>Head Neck Neoplasms</mesh_term>
	<mesh_term>Pembrolizumab</mesh_term>
	<criteria>Men woman ≥ 18 year age Histologically cytologically confirm recurrent , metastatic unresectable HNSCC oral cavity , oropharynx , hypopharynx , larynx either progress platinumbased chemotherapy administer metastatic disease recur within 6 month completion platinumbased neoadjuvant adjuvant therapy Presence radiographically measurable disease define RECIST 1.1 ECOG performance status 0 1 Prior malignancy ( HNSCC ) , except adequately treat basal cell squamous cell skin cancer , situ cervical cancer , cancer subject disease free ≥ 2 year limit survival &lt; 2 year Known central nervous system metastases and/or carcinomatous meningitis A lifethreatening illness , medical condition ( include psychiatric condition ) organ system dysfunction , investigator 's opinion , could compromise subject 's safety Significant cardiovascular disease uncontrolled symptomatic arrhythmia , congestive heart failure , myocardial infarction within 6 month start study drug</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>November 2016</verification_date>
</DOC>